Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML. - Wikidata - awgldk - TriplyDB

Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML.

Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML.

http://www.wikidata.org/entity/Q47755956

about

Mitochondrial metabolic remodeling in response to genetic and environmental perturbations Epigenetic regulators and their impact on therapy in acute myeloid leukemia Epigenetic regulators as promising therapeutic targets in acute myeloid leukemia Epigenetic Modulation as a Therapeutic Prospect for Treatment of Autoimmune Rheumatic Diseases Molecular Connections between Cancer Cell Metabolism and the Tumor Microenvironment 2-Hydoxyglutarate: D/Riving Pathology in gLiomaS Clinical and biological implications of ancestral and non-ancestral IDH1 and IDH2 mutations in myeloid neoplasms The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia Minimal Residual Disease in Acute Myeloid Leukemia: Still a Work in Progress?Gene mutation patterns in patients with minimally differentiated acute myeloid leukemia.DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies Glial progenitors as targets for transformation in glioma.Small molecule inhibitors in acute myeloid leukemia: from the bench to the clinic Genetic dissection of leukemia-associated IDH1 and IDH2 mutants and D-2-hydroxyglutarate in Drosophila.Retrospective review using targeted deep sequencing reveals mutational differences between gastroesophageal junction and gastric carcinomas.The molecular basis of myeloid malignancies.Proto-oncogenic role of mutant IDH2 in leukemia initiation and maintenance.Cancer stem cells as a target population for drug discovery.Investigational cancer drugs targeting cell metabolism in clinical development.A Synthetic Lethal Interaction between Glutathione Synthesis and Mitochondrial Reactive Oxygen Species Provides a Tumor-Specific Vulnerability Dependent on STAT3.Rational Combinations of Targeted Agents in AML The Warburg effect: a balance of flux analysis Targeting DOT1L and HOX gene expression in MLL-rearranged leukemia and beyond TET proteins and 5-methylcytosine oxidation in hematological cancers Detection of Dual IDH1 and IDH2 Mutations by Targeted Next-Generation Sequencing in Acute Myeloid Leukemia and Myelodysplastic Syndromes.Digging deep into "dirty" drugs - modulation of the methylation machinery.High frequency of additional gene mutations in acute myeloid leukemia with MLL partial tandem duplication: DNMT3A mutation is associated with poor prognosis.IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association.The Impact of DNA Methylation in Hematopoietic Malignancies.Molecular Pathways: Isocitrate Dehydrogenase Mutations in Cancer.The oncometabolite R-2-hydroxyglutarate activates NF-κB-dependent tumor-promoting stromal niche for acute myeloid leukemia cells.Acute myeloid leukemia: advancing clinical trials and promising therapeutics.Economic impact of genomic diagnostics for intermediate-risk acute myeloid leukaemia Isocitrate dehydrogenase mutations in myeloid malignancies.Enantiomer-specific and paracrine leukemogenicity of mutant IDH metabolite 2-hydroxyglutarate Stem cell origin of myelodysplastic syndromes.Chromatin modifiers and the promise of epigenetic therapy in acute leukemia Investigational epigenetically targeted drugs in early phase trials for the treatment of haematological malignancies.Integrating genetics and epigenetics in myelodysplastic syndromes: advances in pathogenesis and disease evolution.The mechanistic role of DNA methylation in myeloid leukemogenesis.

P2860

Q26747718-B43EB65B-32D5-452A-8A83-ECEAEF2534D0 Q26765402-B3D07674-C640-4940-9C06-3FD126B4DC2E Q26865149-ECE79F7D-3C2C-4C9D-8BC7-DC9099F59E97 Q28079715-24B1030B-E329-4DBB-88F7-47FC6BD9F9E8 Q28081657-C3C67CC4-824F-4356-AD0F-6F7EEED84EC5 Q28087807-550377DC-6F44-434F-B3DE-0CA01F747F07 Q29039802-D8D8118B-3A2C-4509-8756-23E29BFBF011 Q33796552-0DEC7A15-0B1A-476F-BFF8-D46DC41DF032 Q33832709-6D221577-8034-46CD-A927-3F7D39F058B8 Q34347096-2DBE54B6-5813-4554-A1E9-1DFF6FA40F52 Q34661033-A85D40AD-11C0-4723-B7A8-983310F7A16E Q34735661-A43E8D08-BF82-42B1-87BF-51EAAB425299 Q34817365-EF488777-8615-440B-A4AD-E157005C8C9E Q34876800-A04D3931-5565-49CB-8652-BA618A0C748F Q35067345-79000309-F29C-4B08-8E4C-AB4575C12C3F Q35103708-348AAEEF-CA31-4895-9765-F4EC25F3B690 Q35234477-1A517205-934B-46DC-9165-74A2489A356C Q35390334-8A80D7FF-BF70-427C-AC17-B62AE0F7D2BD Q35615701-11AACCAB-FA7A-4FB6-9DED-B3351592BBEC Q35748498-59E84F12-AAEA-4D19-993B-AC770C0C2180 Q35750491-37A14E88-4D04-481A-83B8-F6E9B4A3BED4 Q35865839-83DFF55D-931B-4174-9682-D0F752E81371 Q35967446-8BB7E8CD-54EB-408E-B009-45CA73191BE7 Q36197509-49E27712-BB5B-491E-A5E0-FA4B664BBB34 Q36240610-E85FF431-0776-408C-B558-AA6330A2F0F3 Q36523796-4CB0C333-D426-46D0-94EE-21DD314B1229 Q36545112-6B89772D-45A0-4A7B-ACF2-749CADC359BE Q36561772-21BE4660-BC63-403C-8F44-967786860A85 Q36724810-1ECF6405-4A6F-4118-8F41-48BCDAED4CCD Q36805635-D55C11C2-F0DE-45EC-A2EE-DFDB2650E19A Q37220616-8C051FAA-0F6B-4D21-99A4-EE8786B41389 Q37221579-F9BD325A-9696-482F-9118-99396C66386F Q37252482-AFDB3494-0E86-4952-A839-BF6735161EF3 Q37625630-99E5AD9A-1ED3-4112-A875-74E4A8CAD050 Q37632016-A6EA1B68-2268-46AE-84D8-9E834EF136CE Q38171230-13F8CE01-8246-4B92-86C8-0B5D0A3EDB50 Q38194444-D08A4693-D3E4-4A43-A31D-ECEA2F12465E Q38214120-0B419C0C-A7F6-4A51-91CD-3C29D53914D9 Q38218055-5C03FD22-CFE9-455F-99AE-152C13259762 Q38218971-31290396-977D-4D12-B657-10F65B81F698

P2860

Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML.

http://www.wikidata.org/entity/Q47755956

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh

2013年學術文章

@zh-hant

name

Mutant IDH1 promotes leukemoge ...... fically targeted in human AML.

@en

Mutant IDH1 promotes leukemoge ...... fically targeted in human AML.

@nl

type

label

Mutant IDH1 promotes leukemoge ...... fically targeted in human AML.

@en

Mutant IDH1 promotes leukemoge ...... fically targeted in human AML.

@nl

prefLabel

Mutant IDH1 promotes leukemoge ...... fically targeted in human AML.

@en

Mutant IDH1 promotes leukemoge ...... fically targeted in human AML.

@nl

P1433

Q47755956-BCEE0596-1D54-43A8-B2B7-E4A6818159C0

P1476

Q47755956-4F32518B-863D-4BCC-9701-E7A32EE7F54F

P2093

Q47755956-0564FE83-7784-4708-BA0E-8A24C3A07450

Q47755956-0C1AAD82-2065-476A-8CA7-D3C90B0001EF

Q47755956-2E03E090-8F47-4D1D-B1CE-1661BDB243D4

Q47755956-2E49C5EA-03D4-4432-B859-D3C030021CC8

Q47755956-39FDC5C1-AF10-4BEB-8627-BF773341877E

Q47755956-4C707853-21B7-465F-93CB-4A426BAE44ED

Q47755956-5369CB22-1EA2-49E2-A481-AB398DE3F3A0

Q47755956-5A5B6D7C-BBEF-48B5-8DB2-CD90E8160ABD

Q47755956-67D89983-BCA2-41A2-8A59-5B467BD37108

Q47755956-6A0B43AB-48AB-4206-A8D1-F2CD7A4C81E0

P304

Q47755956-5A96732D-65D8-4672-BD0C-9A6821958193

P31

Q47755956-A91C03C0-2C38-4393-8B3A-F35949B5440F

P356

Q47755956-BAC970F9-641B-49A9-A5B2-600F736FF99B

P407

Q47755956-78032DE0-C0A6-4BD2-BBA4-842C69B134D2

P433

Q47755956-B30F6A53-A38B-4B9E-9D58-2688AA54804C

P478

Q47755956-7B42E15D-A318-41AB-BC34-DAAB9D955CA5

P50

Q47755956-0950F373-9C64-40F8-B8AC-8BD14AB43553

Q47755956-57437928-1055-4953-B85C-7364F281A1B5

Q47755956-CDCC0770-775C-4861-A30C-18ACFDE3603C

Q47755956-E7EEBF63-C0B0-43BB-898F-DBC9B63539E6

P577

Q47755956-A2541218-60A9-4A09-9352-CB29C69E6521

P5875

Q47755956-1A2218EF-D4BE-4284-A109-3B97B51AB8DB

P698

Q47755956-0FB657E6-A365-4F0A-A9D6-4969271A6496

P356

BLOOD-2013-03-491571

P1433

P1476

Mutant IDH1 promotes leukemoge ...... fically targeted in human AML.

@en

P2093

Adrian Schwarzer

http://www.w3.org/2001/XMLSchema#string

Amit Sharma

http://www.w3.org/2001/XMLSchema#string

Arnold Ganser

http://www.w3.org/2001/XMLSchema#string

Eduard A Struys

http://www.w3.org/2001/XMLSchema#string

Erwin E Jansen

http://www.w3.org/2001/XMLSchema#string

Felicitas Thol

http://www.w3.org/2001/XMLSchema#string

Haiyang Yun

http://www.w3.org/2001/XMLSchema#string

Johann Meyer

http://www.w3.org/2001/XMLSchema#string

Jürgen Krauter

http://www.w3.org/2001/XMLSchema#string

Kerstin Görlich

http://www.w3.org/2001/XMLSchema#string

P304

2877-2887

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2013-03-491571

http://www.w3.org/2001/XMLSchema#string

P407

P433

16

http://www.w3.org/2001/XMLSchema#string

P478

122

http://www.w3.org/2001/XMLSchema#string

P50

Dietmar J. Manstein

Anuhar Chaturvedi

Matthias Preller

P577

2013-08-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

255975198

http://www.w3.org/2001/XMLSchema#string

P698

23954893

http://www.w3.org/2001/XMLSchema#string